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4 scores correlated moderately with the Visual Analogical Scale
of the EQ-5D. The dimensions which measure secondary effects
of immunosupression (Side Effects of Corticosteroids-SEC and
Increased Growth of Gum and Hair-IGGH) showed low corre-
lation with SF-36 and EQ-5D although they correlated with the
episodes of acute rejection (r > 0.4). The correlations with clin-
ical variables were low, but in accordance with expectations. The
correlations of the scores at 3 and 6 months were moderate (r =
0,7). 6 patients suffered initial allograft dysfunction and these
showed worse scores than the rest. Cronbachxs Alpha, which
evaluate the reliability, were: 0.92 for the whole questionnaire;
0.86, LPC; 0.79, LCC; 0.66, CRD; 0.63, SEC; 0.74, IGGH; 0.78,
TAPD. CONCLUSIONS: The feasibility, validity and reliability
of the Spanish version of the ESRD-scl were adequate to evalu-
ate the PHS of kidney transplant bearers.
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OBJECTIVES: To demonstrate the contribution of problems
associated with an overactive bladder; namely continence,
urgency and frequency, on health related quality of life and
utility. METHODS: Patients treated by an academic urology unit
in the UK were sent a self-completed survey that included the
EQ5D and SF36 and urology disease-speciﬁc questions. Poten-
tially confounding factors were controlled using multivariate
linear regression analysis. The survey was undertaken with the
Health Outcomes Data Repository (HODaR) framework, a large
representative dataset linking clinical data to routine QoL and
utility survey responses. RESULTS: In a routine survey without
reminders, 609 surveys were retuned (28% response rate). The
mean age of respondents was 65 years (SD 15.5) and 68% were
male. Sixty percent of valid responses reported some degree of
incontinence. Of these, 60% reported stress incontinence; 85%
had urinary frequency problems and 91% had urgency. Among
the generally continent: 12% reported stress incontinence; 60%
reported frequency problems and 54% reported urgency. Con-
trolling for age, gender and body mass index (BMI), incontinence
was associated with a reduction in the EQ5Dindex (-0.11; SE
0.026, p < 0.001) and SF36 scores across all domains (max:
physical role -14.51 (SE 3.92; p < 0.001)). Under similar ana-
lytic conditions in continent respondents, urgency signiﬁcantly
reduced social and mental-role functioning (-8.55; p = 0.069 &
-14.51; p = 0.080, respectively) whilst frequency reduced the
energy domain (-9.09; p < 0.05). Among the incontinent,
urgency reduced social functioning by -17.61 (p < 0.05), and the
mental domain by -11.58 (p < 0.05) whilst frequency again
reduced the energy domain by -9.07 (p < 0.05). CONCLU-
SIONS: Incontinence has a detrimental impact on quality of life
comparable with diseases and conditions traditionally regarded
as being more serious. Urinary urgency reduces social function-
ing and mental well-being, whilst increased urinary frequency
increases tiredness.
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OBJECTIVE: The I-QOL is a 22-item incontinence-speciﬁc
measure originally developed in the USA and subsequently
adapted into numerous other language versions. The British-
English language version has not yet been validated. The purpose
of this presentation is to report the psychometric performance
characteristics of the UK version of the I-QOL. METHODS: The
I-QOL was included in a cross-sectional, descriptive health out-
comes study among female care-seekers at 17 large primary care
clinics throughout the UK. A total of 2400 women between 18
and 91 years of age took the survey while waiting to be seen by
their care providers. Twenty-two percent (n = 503) of these
women reported symptoms of stress urinary incontinence; 21%
(n = 538) mixed; and 4% (n = 85) urge incontinence without
overactive bladder. Other measures included the Scale for Activ-
ity Interference and Limitation (SAIL, incontinence-speciﬁc indi-
vidualized activity limitations), the Symptom Frequency and
Bothersomeness scale (SFB-SUI), self-perceived severity, self-
reported episodes, and a variety of other demographic and
descriptive variables. Psychometric testing was conducted using
standardized procedures. Reproducibility could not be assessed
within the study design. RESULTS: Principal component analy-
ses conﬁrmed the original measurement model of three subscales
(avoidance and limiting behavior, psychosocial impacts, and
social embarrassment) and a total summary score. Internal con-
sistency values were acceptable (alpha ranged between 0.87 and
0.95) and, as hypothesized, the I-QOL had strong associations
with both the SFB-SUI (symptoms) (>0.60) and the SAIL (limi-
tations) (>0.67) scales. Quality of life scores became signiﬁcantly
worse as the patients’ perception of severity increased (p < 0.001)
and number of incontinent episodes increased (p < 0.001). CON-
CLUSION: This cross-sectional assessment of the British-English
version has shown it to have similar psychometric performance
to those previously published for the original measure, making
this I-QOL language version a valid PRO for incorporation in
community based studies of patients with varying types and
severity of urinary incontinence.
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OBJECTIVES: To investigate the impact of long-term treatment
with darifenacin, a muscarinic M3 selective receptor antagonist,
on quality of life (QoL) in patients with overactive bladder
(OAB). METHODS: Patients with OAB for ≥6 months who par-
ticipated in two 12-week, placebo-controlled, double-blind
feeder studies of darifenacin controlled release 3.75, 7.5 or 15
mg qd were enrolled into this 2-year, multicentre, open-label
extension. During the ﬁrst 2 weeks of the extension all patients
received darifenacin 7.5mg, after which titration between dar-
ifenacin 15 and 7.5mg was permitted. The King’s Health Ques-
tionnaire [KHQ] was used to assess QoL. Here, we report data
from patients who received darifenacin 7.5 or 15mg during the
feeder studies and had a gap of £3 treatment days before enter-
ing the extension. RESULTS: A total of 303 patients who had
received darifenacin 7.5 or 15mg during the feeder studies
entered the extension (22–89 years; 86.5% female) and 199
patients (65.7%) completed the study. Darifenacin 7.5/15mg
was associated with signiﬁcant improvements in eight of nine
KHQ domains (Incontinence impact, Severity measures, Role
limitations, Physical limitations, Social limitations, Emotions,
Personal relationships and Sleep/energy) from baseline to the end
of the 12-week, double-blind feeder studies (all p < 0.001 vs.
